6 minute read
Mar. 20, 2024
Zilucoplan (ZILBRYSQ): The First Approved Drug Derived from mRNA Display for Cyclic Peptides
zilucoplan
subcutaneous C5 inhibitor approved for myasthenia gravis from mRNA display screening Press Release, October 2023 Ra Pharmaceuticals, Cambridge, MA / UCB, Brussels, BE
Loading...
